acute-kidney-injury
Does blocking IRE1/JNK calm ferroptosis in AKI?
Open access · cc by · source: Europe PMC
In I/R mice and H/R HK-2 cells, IRE1/JNK activation tracked with ferroptosis; inhibiting the pathway improved BUN/creatinine and ferroptosis markers.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Triggering tumor ferroptosis can help checkpoint therapy in cold tumors (preclinical).
In EGFR-mutant NSCLC models, cisplatin-driven tumor ferroptosis polarized N1 neutrophils and supported T-cell/Th1 programs that synergized with immune checkpoint inhibitor therapy.
Scope note — renal protection restrains ferroptosis — opposite therapeutic direction from oncology induction
Limits the claim's scope: a different population, assay, or outcome.
Blocking IRE1/JNK can attenuate ferroptosis-linked renal I/R injury in mice/cells.
Renal ischemia/reperfusion activated IRE1/JNK with ferroptotic tubular injury; inhibiting that axis improved BUN/creatinine and ferroptosis markers, aligning with ferrostatin-1-style protection.
Evidence for the claim as stated.
Cisplatin-induced ferroptosis aided ICI efficacy in cold tumors vs IRE1/JNK blockade reduced ferroptosis-linked kidney I/R injury
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Cisplatin-induced ferroptosis aided ICI efficacy in cold tumors vs IRE1/JNK blockade reduced ferroptosis-linked kidney I/R injury
- Supports · How does cisplatin boost checkpoint therapy?
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Ferroptosis
In EGFR-mutant NSCLC models, cisplatin-driven tumor ferroptosis polarized N1 neutrophils and supported T-cell/Th1 programs that synergized with immune checkpoint inhibitor therapy.
Placed as supporting evidence on Ferroptosis
Renal ischemia/reperfusion activated IRE1/JNK with ferroptotic tubular injury; inhibiting that axis improved BUN/creatinine and ferroptosis markers, aligning with ferrostatin-1-style protection.
Study at a glance
- Design
- Animal / in-vitro — Mouse renal ischemia–reperfusion plus hypoxia/reoxygenation in HK-2 cells; IRE1/JNK and ferroptosis
- N
- Animal and cell experiments; no single human N
- Population
- Mice with renal ischemia–reperfusion injury and cultured human tubular epithelial cells
- Outcome
- Ferroptosis in acute kidney injury after IRE1/JNK pathway inhibition
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Does blocking IRE1/JNK calm ferroptosis in AKI?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
144 male C57BL/6J mice were used for the I/R model.
One hundred and forty-four healthy male, eight-weeks-old C57BL/6J mice (20–25 g in mass) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.
Ferrostatin-1 was given at 0.8 mg/kg before I/R.
Ferrostatin-1 (Fer-1, 0.8 mg/kg, Sigma-Aldrich Chemical, Darmstadt, Germany), a ferroptosis inhibitor, was dissolved in DMSO and 0.9% NaCl and injected into mice via tail vein at 24 h before I/R.
Key findings
I/R caused abnormal renal function, tubular injury, IRE1/JNK activation, and ferroptosis; H/R cells showed ROS and ferroptotic mitochondria. IRE1/JNK inhibition lowered BUN/creatinine/injury and shifted ferroptosis markers; ferroptosis inhibition also attenuated IRE1/JNK.
Methodology
Modeled AKI with renal ischemia-reperfusion in 144 mice and hypoxia/reoxygenation in HK-2 cells, then inhibited IRE1/JNK or ferroptosis (e.g., Fer-1) to test cross-talk.
Limitations
Mouse/cell protection is not yet a clinical AKI therapy; timing, off-target effects, and human translation remain open.
Related papers in this topic
Same topic cluster — not a recommendation engine.